Cynbiose
Cynbiose is a European Contract Research Organization (CRO) dedicated to preclinical research services with a core expertise in non-human primate (NHP) models. The company focuses on bridging the gap between preclinical and clinical development through innovative models, especially for infectious respiratory diseases and brain disorders. They offer customized, high-quality services and collaborate closely with partners to support biomedical research and drug development.
Industries
Nr. of Employees
small (1-50)
Cynbiose
Sainte-Consorce, Auvergne-Rhône-Alpes, France
Products
Platform for blood–brain barrier penetration studies
Integrated experimental platform to evaluate BBB crossing and central exposure in NHPs using sequential CSF sampling, cerebral microdialysis, and parallel blood sampling.
Central Pharmacokinetics
Preclinical service for the in vivo and ex vivo assessment of CNS drug bioavailability and blood-brain barrier crossing using non-human primate models.
Gene Therapies and ATMPs Preclinical Assessment Services
Dedicated preclinical solutions for assessing viral and non-viral gene therapy candidates and oncolytic viruses using non-human primate (NHP) models.
Thérapies géniques (GTMP)
Solution dédiée pour l'évaluation préclinique des médicaments de thérapie génique (GTMP) utilisant des primates non humains (PNH).
Cynbiose Preclinical Research Services
Specialized preclinical research services and innovative non-human primate models designed to accelerate the preclinical development of drug candidates.
KineC3
Proprietary platform dedicated to the study of the crossing of the blood-brain barrier (BBB) for drug candidates targeting the central nervous system, utilizing in vivo exploration techniques and methods for central pharmacokinetics studies.
Platform for blood–brain barrier penetration studies
Integrated experimental platform to evaluate BBB crossing and central exposure in NHPs using sequential CSF sampling, cerebral microdialysis, and parallel blood sampling.
Central Pharmacokinetics
Preclinical service for the in vivo and ex vivo assessment of CNS drug bioavailability and blood-brain barrier crossing using non-human primate models.
Gene Therapies and ATMPs Preclinical Assessment Services
Dedicated preclinical solutions for assessing viral and non-viral gene therapy candidates and oncolytic viruses using non-human primate (NHP) models.
Thérapies géniques (GTMP)
Solution dédiée pour l'évaluation préclinique des médicaments de thérapie génique (GTMP) utilisant des primates non humains (PNH).
Cynbiose Preclinical Research Services
Specialized preclinical research services and innovative non-human primate models designed to accelerate the preclinical development of drug candidates.
KineC3
Proprietary platform dedicated to the study of the crossing of the blood-brain barrier (BBB) for drug candidates targeting the central nervous system, utilizing in vivo exploration techniques and methods for central pharmacokinetics studies.
Services
Design and execution of systemic and central pharmacokinetic and pharmacodynamic studies, including ADME and biodistribution assessments.
Customized efficacy model design and execution in NHPs to evaluate therapeutic activity and support clinical translation.
Non-GLP early safety evaluations to assess tolerability and identify potential safety signals prior to larger GLP studies or clinical entry.
Platform services for assessing blood–brain barrier crossing and central exposure using CSF sequential sampling, cerebral microdialysis, and brain ECF measurements in conscious NHPs.
Preclinical assessment of inhaled product delivery and therapeutic impact in respiratory disease NHP models.
Integrated collection, handling and coordination of biological samples (blood, CSF, tissue, ECF) to support biomarker, PK and pathology analyses.
Design and execution of systemic and central pharmacokinetic and pharmacodynamic studies, including ADME and biodistribution assessments.
Customized efficacy model design and execution in NHPs to evaluate therapeutic activity and support clinical translation.
Non-GLP early safety evaluations to assess tolerability and identify potential safety signals prior to larger GLP studies or clinical entry.
Platform services for assessing blood–brain barrier crossing and central exposure using CSF sequential sampling, cerebral microdialysis, and brain ECF measurements in conscious NHPs.
Preclinical assessment of inhaled product delivery and therapeutic impact in respiratory disease NHP models.
Integrated collection, handling and coordination of biological samples (blood, CSF, tissue, ECF) to support biomarker, PK and pathology analyses.
Expertise Areas
- Translational non-human primate (NHP) model development
- PK/PD and biodistribution studies in NHPs
- CNS drug development and blood–brain barrier penetration assessment
- Preclinical efficacy model design and proof-of-concept
Key Technologies
- Non-human primate (NHP) translational models
- Sequential cerebrospinal fluid (CSF) sampling
- Cerebral microdialysis
- Brain extracellular fluid (ECF) pharmacokinetics
News & Updates
Event on June 16, 2025, in Boston, USA.
Event on June 25, 2025, in Tours, France.
A study on a non-human primate model for COVID-19 developed by Cynbiose, showing its potential for infectious disease research.
Celebrated the opening of a state-of-the-art facility supporting biotherapies, vaccines, and gene therapies, especially in infectious diseases and CNS disorders.
Event on June 16, 2025, in Boston, USA.
Event on June 25, 2025, in Tours, France.
A study on a non-human primate model for COVID-19 developed by Cynbiose, showing its potential for infectious disease research.
Celebrated the opening of a state-of-the-art facility supporting biotherapies, vaccines, and gene therapies, especially in infectious diseases and CNS disorders.